Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology

Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) lead to synthetic lethality when used in cancers harbouring a BRCA mutation or homologous recombination deficiency. There are now four PARPi approved by the Food and Drug Administration for therapeutic use is ovarian and breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Mweempwa, Angela, Wilson, Michelle K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992504/
https://www.ncbi.nlm.nih.gov/pubmed/35582591
http://dx.doi.org/10.20517/cdr.2019.50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992504/
https://www.ncbi.nlm.nih.gov/pubmed/35582591
http://dx.doi.org/10.20517/cdr.2019.50

Ejemplares similares